eSource Data: The Path to Efficiency

eSource (or electronic source data) is up and coming in the healthcare and clinical trial industry. This paper will cover the benefits of eSource compared to standard paper source, challenges of eSource adoption and how far can technology support the expansion of eSource.
Sponsor: ClinCapture

FOCUS 5: NEXT-GEN mHEALTH

BBK Worldwide’s eBook offers firsthand perspectives from leading innovators on the current state of mHealth and its future potential in shaping the increasingly complex and patient-centric healthcare landscape. Industry experts from the Michael J. Fox Foundation, Be the Partner, Landon Pediatric Foundation and Apptomics weigh in on the challenges and opportunities in the implementation and evolution of mobile healthcare solutions.
Sponsor: BBK Worldwide

The 8 Signs You’re With The Wrong Clinical Data Software Provider

It's common for clinical researchers to experience data platform "buyer's remorse" at some point or another. But how do you know if it's merely a feeling or a sign of bigger problems? In this eGuide, we lay out 8 of the most common warning signs that indicate it's time to switch EDC software vendors and step you through the process of researching, pricing, and demoing new ones.
Sponsor: Merge, an IBM Company

Which Modality is the Most Effective for My eCOA Study

When a protocol calls for the collection of clinical outcome assessments, there are a number of factors which you must consider when it comes to deciding which method to implement in order to achieve the highest quality data outcomes. This eBook is designed to increase your knowledge about the range of eCOA modalities available in the market and aims to help you partner with your eCOA vendor to make well-informed choices regarding the best option for your unique study parameters.
Sponsor: CRF Health

Clinical Development: Rare Disease

According to Global Genes, more than 350 million people worldwide suffer from rare diseases. Unfortunately, according to the FDA’s Every Life Foundation, only around 5% of rare diseases have a FDA-approved treatment.Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, has worked on more than 245 rare disease studies in 96 countries since 2010. Here, Laurie Witherwax outlines the patient-centric approach that Quintiles deploys to help pharmaceutical and biotechnology companies get new therapies to patients.
Sponsor: Quintiles

Quintiles Precision Enrollment: a faster, more effective approach to patient recruitment.

Finding patients as quickly as possible is key to managing the cost and time pressures associated with clinical trials. Learn how to find the right sites and the right patients within 21 days.
Sponsor: Quintiles

Quintiles Precision Enrollment: expand your patient recruitment population.

Watch this brief animated video to learn how Quintiles’ Precision Enrollment can help reduce your study start up by opening sites to studies only when they have a qualified patient. The right sites. The right patients. Within 21 days.

Sponsor: Quintiles

Transforming Patient Recruitment through Patient and Site Engagement

11% of research sites industry-wide fail to enroll a single patient and 37% of sites under-enroll, wasting time and money that does not benefit sponsors. Bernadette Tosti, Senior Director of Patient Recruitment, Quintiles, will address the various ways Quintiles is pioneering early planning, forming new and innovative relationships, and using new technology and communication tools to create more effective physician networks with a focus on patient engagement.

Live Webcast: Tuesday, August 23, 2016 at 11am EDT

Simplifying the Complexities of Global Rare Disease Drug Development

Join Quintiles experts Dr. Cynthia Jackson and Sheetal Telang as they share best practices helping biopharmaceutical companies overcome the global complexities of putting rare disease drugs through development by offering solutions for accelerating the availability of new treatments for patients and their families who need them most.

Live Webcast: Thursday, September 15, 2016 at 11 am EDT

The State of Risk-based Monitoring (RBM)

Risk-based monitoring (RBM) is disrupting clinical development on every level. Hear experts explain the challenges faced in implementing RBM studies and the latest technology capabilities to help you execute your studies with confidence.

Live Webcast: Recorded on June 21, 2016